Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax makes progress on avian flu vaccine
“Our VLP (virus-like particle) technology, based on a scalable process with short production lead times, offers an attractive alternative to the existing egg-dependent and the newer cell-based methods
“Our VLP (virus-like particle) technology, based on a scalable process with short production lead times, offers an attractive alternative to the existing egg-dependent and the newer cell-based methods
Under the collaboration, SIRS-Lab will provide access to selected biomarkers for sepsis. Biosite will then make antibodies to those selected targets using the company’s proprietary antibody development process,
The study will be conducted at the European Pancreas Center of the University of Heidelberg Clinic for Surgery. Enrolment will include up to 43 patients with advanced, inoperable
The FDA approval to expand to the final phase of the clinical trial was based on Refocus Group’s submission of preliminary data from phase II surgeries through mid-July
There are concerns that a strain of the H5N1 virus, which infects poultry, could be carried west by migrating wild birds. The virus, which is thought to have
The randomized, double-blind trial will compare the efficacy and safety of Alinia to that of a placebo. Alinia will be administered orally as a single 500 mg tablet
The heart defect being studied is known as Patent Foramen Ovale (PFO), a structural defect where a small hole between the right and left atria (upper chambers of
“The significance of this joint venture is that it now links a low-cost producer, with a huge manufacturing capacity,” Said Dr Frank Leung, Coremed’s founder. “Combined, this will
EndoTAG-1 is a combination of paclitaxel (sold as Taxol by Bristol-Myers Squibb) and a unique carrier system which targets paclitaxel to newly formed blood vessels. EndoTAG aims at
During the collaboration the researchers will combine Ciphergen’s biomarker discovery and diagnostic process with the university’s clinical expertise. As part of the collaboration, Ciphergen receives exclusive rights to